http://rdf.ncbi.nlm.nih.gov/pubchem/patent/PL-218235-B1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fc7fa5cc95fc560137f570dc5a2ac906 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e77fe6d1d93f1aeffa1009446386c843 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_54cf21328639716856d474a8aec64934 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2a26a9ce9b8661079b9031f44196fe33 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b21fcd5a18ce0e890e28987c73ac9530 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ed1381d0a8666a6e34868f06fe50fda4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8858a27fd10fb9b5cc3728c0256458d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be3e8fc83ec197446fc2053b1dbcfe72 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-3616 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61L27-225 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L27-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L24-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61L15-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| filingDate | 2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_204b17955a6c99d210bc3abd8949ba7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c537114e7e85051c56141aaded302898 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_61dfd41585dc0676e0fbbda5685130a2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_188444a386ddca830c39bf52b9d18d99 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84010575c49c0d8d66d656b57e67c19c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b816f19d9e6f38a8c691e89fed29c70e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebf4824f9fd29fc95313dd5643ece7e8 |
| publicationDate | 2014-10-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | PL-218235-B1 |
| titleOfInvention | Autologous and allogenic fibrin carrier, method of its preparation and application of fibrin carrier for cell transplantation, especially in human cells |
| abstract | An autologous and allogenic fibrin carrier characterized in that it is a gel-like mixture of fibrinogen and platelet-rich plasma combined at a ratio 0.1-2 to 0.1 -2, favorably 1 : 1 of volume share, and a calcium chloride in a 0.1-99% solution, favorably a 10% solution at a ratio 0.1-2 to 0.1-2, favorably 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. A method of obtaining an autologous fibrin carrier comprising blood collection, separation of blood plasma from blood cells, freezing and thawing of blood plasma, characterized in that the blood donation collected from the blood donor is separated from the concentrate of blood cells, i.e. erythrocytes, leukocytes being removed, said separation having the form of centrifugation at + 20 to + 24°C for 5 to 15 minutes, with centrifugation force of 700 to 2000 x g; afterwards plasma is pushed through to an empty satellite container, wherein centrifugation takes place at + 20°C to +24°C for 5-15 minutes at a centrifugation force of 2100 to 5000 x g to separate platelet-rich plasma, which is stored in bags, favorably breathable swinging bags for maximum 7 days and favorably 3 days. The remaining platelet-poor plasma is used for preparation of fibrinogen in cryoprecipitate, by freezing blood plasma twice to the temperature of -30°C to -90°C and thawing blood plasma at about + 4°C, for example in a water bath, then it is centrifuged at about + 4°C for 5-20 minutes at centrifugation force of 1000 to 5000 x g, wherein supernatant is removed and resultant cryoprecipitate is mixed with platelet-rich plasma from the container, at a ratio from 0.1 -2 to 0.1 -2, favorably 1 : 1, and with a calcium compound solution, favorably a 10% calcium chloride solution at a favorable ratio 1 : 1 relative to the mixture of fibrinogen and platelet-rich plasma. Use of an autologous fibrin carrier for obtaining a gel-like transplant, that is a carrier formed by mixing fibrinogen and platelet-rich plasma obtained from the recipient's blood, favorably of a single donation, or ready-made fibrinogen characterized by an adequate phenotype and platelet-rich plasma taken directly from the blood donation of the patient-recipient using the operating room's apparatus, wherein in the process of obtaining a carrier and prior to the addition of a 0.1%-99% calcium chloride solution at a ratio 0.1 -2 do 0.1-2, favorably 1 : 1 of volume share relative to the mixture of fibrinogen and platelet-rich plasma, from 5 thousand to 100 million recipient's cells or allogenic and xenogenic cells are added, cultured in a known way and processed on the transplantation's date by trypsinization, washing in a serum- containing medium and vitality assessment. |
| priorityDate | 2011-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 54.